Mr. Chair, more vulnerable Canadians continue to be let down. There are effective medications that have been developed for those living with cystic fibrosis, yet this medication is not available here. We know that the pharmaceutical company has not been able to apply to market this drug in Canada because of the changes to the PMPRB, which have been heavily criticized by stakeholders and patients.
Will the minister delay the July 1 implementation date and review the regulations so that drugs like Trikafta are made available in Canada?